257 related articles for article (PubMed ID: 10813718)
1. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma.
Karczewska A; Nawrocki S; Breborowicz D; Filas V; Mackiewicz A
Cancer; 2000 May; 88(9):2061-71. PubMed ID: 10813718
[TBL] [Abstract][Full Text] [Related]
2. Expression of interleukin-6, interleukin-6 receptor (gp80), and the receptor's signal-transducing subunit (gp130) in human normal pituitary glands and pituitary adenomas.
Kurotani R; Yasuda M; Oyama K; Egashira N; Sugaya M; Teramoto A; Osamura RY
Mod Pathol; 2001 Aug; 14(8):791-7. PubMed ID: 11504839
[TBL] [Abstract][Full Text] [Related]
3. A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA.
Oh JW; Revel M; Chebath J
Cytokine; 1996 May; 8(5):401-9. PubMed ID: 8726669
[TBL] [Abstract][Full Text] [Related]
4. Cytokines oncostatin M and interleukin 1 regulate the expression of the IL-6 receptor (gp80, gp130).
Geisterfer M; Richards CD; Gauldie J
Cytokine; 1995 Aug; 7(6):503-9. PubMed ID: 8580365
[TBL] [Abstract][Full Text] [Related]
5. gp130-specific antisense oligonucleotides inhibit IL-6 signal inducing junB mRNA transcription in the human hepatoma cell line, HepG2.
Varga VL; Fülöp AK; Holub MC; Tóth S; Szalai C; Falus A
Cell Biol Int; 2001; 25(8):835-40. PubMed ID: 11482910
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-6 -174G-->C polymorphism is associated with improved outcome in high-risk breast cancer.
DeMichele A; Martin AM; Mick R; Gor P; Wray L; Klein-Cabral M; Athanasiadis G; Colligan T; Stadtmauer E; Weber B
Cancer Res; 2003 Nov; 63(22):8051-6. PubMed ID: 14633738
[TBL] [Abstract][Full Text] [Related]
7. A combination of interleukin-6 and its soluble receptor impairs sperm motility: implications in infertility associated with endometriosis.
Yoshida S; Harada T; Iwabe T; Taniguchi F; Mitsunari M; Yamauchi N; Deura I; Horie S; Terakawa N
Hum Reprod; 2004 Aug; 19(8):1821-5. PubMed ID: 15166129
[TBL] [Abstract][Full Text] [Related]
8. Resistance to interleukin 6 in human non-small cell lung carcinoma cell lines: role of receptor components.
Ganapathi MK; Weizer AK; Borsellino S; Bukowski RM; Ganapathi R; Rice T; Casey G; Kawamura K
Cell Growth Differ; 1996 Jul; 7(7):923-9. PubMed ID: 8809410
[TBL] [Abstract][Full Text] [Related]
9. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis.
Barbareschi M; Maisonneuve P; Aldovini D; Cangi MG; Pecciarini L; Angelo Mauri F; Veronese S; Caffo O; Lucenti A; Palma PD; Galligioni E; Doglioni C
Cancer; 2003 Aug; 98(3):474-83. PubMed ID: 12879463
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-6 receptor signaling. I. gp80 and gp130 receptor interaction in the absence of interleukin-6.
Gaillard JP; Mani JC; Liautard J; Klein B; Brochier J
Eur Cytokine Netw; 1999 Mar; 10(1):43-8. PubMed ID: 10210772
[TBL] [Abstract][Full Text] [Related]
12. In vivo modulation of soluble "antagonistic" IL-6 receptor synthesis and release in ESRD.
Memoli B; Grandaliano G; Soccio M; Postiglione L; Guida B; Bisesti V; Esposito P; Procino A; Marrone D; Michael A; Andreucci M; Schena FP; Pertosa G
J Am Soc Nephrol; 2005 Apr; 16(4):1099-107. PubMed ID: 15716332
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6.
Peters M; Blinn G; Solem F; Fischer M; Meyer zum Büschenfelde KH; Rose-John S
J Immunol; 1998 Oct; 161(7):3575-81. PubMed ID: 9759879
[TBL] [Abstract][Full Text] [Related]
14. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
Utada Y; Haga S; Kajiwara T; Kasumi F; Sakamoto G; Nakamura Y; Emi M
Cancer; 2000 Mar; 88(6):1410-6. PubMed ID: 10717624
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-6 receptor antagonists inhibit interleukin-11 biological activity.
Sun RX; Gennaro C; Rocco S; Gu ZJ; Klein B
Eur Cytokine Netw; 1997 Mar; 8(1):51-6. PubMed ID: 9110148
[TBL] [Abstract][Full Text] [Related]
16. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
Di Saverio S; Gutierrez J; Avisar E
Breast Cancer Res Treat; 2008 Oct; 111(3):541-7. PubMed ID: 18026874
[TBL] [Abstract][Full Text] [Related]
17. Differential regulation of gastric tumor growth by cytokines that signal exclusively through the coreceptor gp130.
Howlett M; Judd LM; Jenkins B; La Gruta NL; Grail D; Ernst M; Giraud AS
Gastroenterology; 2005 Sep; 129(3):1005-18. PubMed ID: 16143138
[TBL] [Abstract][Full Text] [Related]
18. Image cytometric bcl-2:bax and bcl-2:bcl-x ratios in invasive breast carcinoma: correlation with prognosis.
Schiller AB; Clark WS; Cotsonis G; Lawson D; DeRose PB; Cohen C
Cytometry; 2002 Aug; 50(4):203-9. PubMed ID: 12210599
[TBL] [Abstract][Full Text] [Related]
19. High MMP-1 mRNA expression is a risk factor for disease-free and overall survivals in patients with invasive breast carcinoma.
Cheng S; Tada M; Hida Y; Asano T; Kuramae T; Takemoto N; Hamada J; Miyamoto M; Hirano S; Kondo S; Moriuchi T
J Surg Res; 2008 May; 146(1):104-9. PubMed ID: 17663001
[TBL] [Abstract][Full Text] [Related]
20. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
